{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:57:38Z","timestamp":1762005458036},"reference-count":13,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2023]]},"DOI":"10.3960\/jslrt.23015","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T22:15:19Z","timestamp":1690496119000},"page":"197-200","source":"Crossref","is-referenced-by-count":1,"title":["Infections associated with bendamustine and anti-CD20 antibody in                    untreated follicular lymphoma: a real-world study"],"prefix":"10.3960","volume":"63","author":[{"given":"Masuho","family":"Saburi","sequence":"first","affiliation":[{"name":"Department of Hematology, Oita Prefectural                            Hospital, Oita, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Okuhiro","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oita University                            Hospital, Oita, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsumi","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oita University                            Hospital, Oita, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takami","family":"Haruyama","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oita University                            Hospital, Oita, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yui","family":"Moroga","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oita University                            Hospital, Oita, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Yanai","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oita University                            Hospital, Oita, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhito","family":"Itani","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oita University                            Hospital, Oita, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuniko","family":"Takano","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oita University                            Hospital, Oita, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhei","family":"Honda","sequence":"additional","affiliation":[{"name":"Department of Hematology, JCHO Nankai Medical                            Center, Oita, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Ono","sequence":"additional","affiliation":[{"name":"Department of Hematology, Almeida Memorial                            Hospital, Oita, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manami","family":"Iwanaga","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oita Kouseiren                            Tsurumi Hospital, Oita, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitohiro","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oita Kouseiren                            Tsurumi Hospital, Oita, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miyuki","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oita Kouseiren                            Tsurumi Hospital, Oita, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Kohno","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oita Kouseiren                            Tsurumi Hospital, Oita, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Nakayama","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oita Kouseiren                            Tsurumi Hospital, Oita, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Ohtsuka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oita Prefectural                            Hospital, Oita, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Ogata","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oita University                            Hospital, Oita, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","unstructured":"1 Jaffe ES, Harris NL, Swerdlow SH, et al.                    Follicular lymphoma. WHO classi\ufb01cation of tumours of haematopoietic and lymphoid                    tissues. Revised Fourth Edition, Lyon, IARC Press. 2017; pp.                    266-277."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Rummel                            MJ,                                Niederle                            N,                                Maschmeyer                            G                    <i>et al.<\/i> Bendamustine plus rituximab versus CHOP plus rituximab                    as first-line treatment for patients with indolent and mantle-cell lymphomas: an                    open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet.                    2013; 381: 1203-1210.","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Derenzini                            E,                                Zinzani                            PL,                                Cheson                            BD.                    Bendamustine: role and evidence in lymphoma therapy, an overview. Leuk Lymphoma.                    2014; 55: 1471-1478.","DOI":"10.3109\/10428194.2013.842986"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Gil                            L,                                Kazmierczak                            M,                                Kroll-Balcerzak                            R,                                Komarnicki                            M.                    Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma. Med                    Oncol. 2014; 31: 944.","DOI":"10.1007\/s12032-014-0944-1"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Gafter-Gvili                            A,                                Polliack                            A. Bendamustine                    associated immune suppression and infections during therapy of hematological                    malignancies. Leuk Lymphoma. 2016; 57: 512-519.","DOI":"10.3109\/10428194.2015.1110748"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Marcus                            R,                                Davies                            A,                                Ando                            K                    <i>et al.<\/i> Obinutuzumab for the first-line treatment of follicular                    lymphoma. N Engl J Med. 2017; 377: 1331-1344.","DOI":"10.1056\/NEJMoa1614598"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Paszkiewicz-Kozik                            E,                                Hus                            I,                                Palka                            M                    <i>et al.<\/i> Early efficacy and safety of obinutuzumab with                    chemotherapy in previously untreated patients with follicular lymphoma: A                    real-world retrospective report of the Polish Lymphoma Research Group. Adv Clin                    Exp Med. 2023; 32: 131-136.","DOI":"10.17219\/acem\/157290"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Galusic                            D,                                Basic-Kinda                            S,                                Pijuk                            A                    <i>et al.<\/i> Efficacy and safety of obinutuzumab-chemotherapy                    combinations in front-line treatment of follicular non-Hodgkin lymphoma during                    the COVID-19 pandemic: a study of KROHEM, the Croatian Cooperative Group for                    Hematologic Diseases. HemaSphere. 2022; 6:                    e807.","DOI":"10.1097\/HS9.0000000000000807"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Ardeshna                            KM,                                Qian                            W,                                Smith                            P                    <i>et al.<\/i> Rituximab versus a watch-and-wait approach in patients                    with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label                    randomised phase 3 trial. Lancet Oncol. 2014; 15: 424-435.","DOI":"10.1016\/S1470-2045(14)70027-0"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Kanda                            Y. Investigation                    of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone                    Marrow Transplant. 2013; 48: 452-458.","DOI":"10.1038\/bmt.2012.244"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Yamasaki                            S,                                Kohno                            K,                                Kadowaki                            M,                                Takase                            K,                                Iwasaki                            H.                    Cytomegalovirus retinitis in relapsed or refractory low-grade B cell lymphoma                    patients treated with bendamustine. Ann Hematol. 2017; 96:                    1215-1217.","DOI":"10.1007\/s00277-017-3005-y"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Hasegawa                            T,                                Aisa                            Y,                                Shimazaki                            K,                                Nakazato                            T.                    Cytomegalovirus reactivation with bendamustine in patients with low-grade B-cell                    lymphoma. Ann Hematol. 2015; 94: 515-517.","DOI":"10.1007\/s00277-014-2182-1"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Hiddemann                            W,                                Barbui                            AM,                                Canales                            MA                    <i>et al.<\/i> Immunochemotherapy with obinutuzumab or rituximab for                    previously untreated follicular lymphoma in the GALLIUM study: influence of                    chemotherapy on efficacy and safety. J Clin Oncol. 2018; 36:                    2395-2404.","DOI":"10.1200\/JCO.2017.76.8960"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/63\/3\/63_23015\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T05:06:23Z","timestamp":1696050383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/63\/3\/63_23015\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.23015","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"23015"}}